Benefit-Risk Assessment

Do your product’s benefits outweigh its potential risks? More importantly, do you have the right data to credibly demonstrate this to regulators, payers, physicians, and patients?

You can rely on our experienced team to help you navigate the ever-evolving landscape of benefit-risk assessment and meet the requirements of regulatory and reimbursement stakeholders worldwide. Our integrated team of cross-functional experts can provide you with the guidance you need to synthesize, summarize, and confidently act on the relevant evidence for your product. We’ll help you build consensus within your organization to achieve a common understanding, increased transparency, and improved communication about your product’s benefit-risk profile.

A Structured Approach Tailored to Your Needs

Our teams have the expertise essential for developing a robust plan to assess benefits and risks. Once we have helped you develop a complete picture of your data, we can help you identify gaps to inform a strategy for possible new studies to include in your clinical development program and clarify appropriate post-approval activities. This includes:

The Value of Proactive Implementation

Conducting credible benefit-risk assessments presents unique challenges because the data on risks and benefits are not usually measured together in the same studies or study populations, and are not often gathered in a real-world setting. Additionally, these measurements might not be collected in the same way in both short and long-term studies or using the same units. By engaging with our team early in the development lifecycle, we can help you account for these challenges and avoid costly re-work and lost time at a critical stage in your product’s development process—while helping you position your product with strong benefit-risk evidence that resonates with your audience.

Recent Publications

Gilsenan AW, Brainsky A, Colilla S. Applying CIRS-BRAT framework in a regulatory setting: updated benefit-risk assessment for fibrinogen concentrate in the setting of complex cardiac surgery. Poster to be given at the 35th Annual ICPE Conference; August 28, 2019. Philadelphia, PA

Gilsenan AW, Ritchey ME, Hauber B, Andrews EB. Considerations when applying a structured benefit-risk assessment to drug delivery combination products. Poster to be given at the 35th Annual ICPE Conference; August 28, 2019. Philadelphia, PA.

Boeri M, Hauber B. Threshold technique: an important tool to quantify and incorporate preferences in benefit-risk analysis. Presented at the 2019 PSI Conference; June 3, 2019. London, UK.

Krueger WS, Young JC, Hollis K, Hauber AB, Gilsenan A, Ritchey ME. Limitations in reporting "benefit-risk" across therapeutic areas in medical device literature. Poster presented at the 34th Annual ICPE Conference; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):515.

Ritchey ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS. Reporting of "Benefit-Risk" studies for medical devices in published literature. Poster presented at the ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S175. doi: 10.1016/j.jval.2018.04.1167.

Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: FL. CRC Press; 2013. p.153-64.

Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011 Feb 1;89(2):217-24. doi: 10.1038/clpt.2010.280.

See more…